RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Ascletis BioScience, the Hangzhou biopharma with a novel treatment for hepatitis C, may raise as much as $457 million in its upcoming Hong Kong IPO, a debut offering that values the company at $2 billion. Ascletis will be the first biotech to stage an IPO under Hong Kong’s new pre-revenue IPO listing rules. The company plans to offer 224 million shares at between HK$12 and HK$16 each. Further, it was announced that GIC Pte, Singapore’s sovereign wealth fund, will buy $75 million of Ascletis’ stock as a cornerstone investor.
Source: China Biotoday
